Led · Series A · Jun 2026

Maneva builds a data and control layer for manufacturing that leverages proprietary physical AI and vision-language models to convert existing camera infrastructure into real-time operational intelligence. Its models, VITA and ALIS, run on NVIDIA edge devices and integrate with sensors and equipment signals to detect safety issues, bottlenecks and inefficiencies, diagnose root causes, and trigger automated responses across machinery, workflows and teams. The company serves customers across confectionery, wood, glass, steel, meat processing, food and beverage, pharmaceuticals, cosmetics and distribution sectors. Maneva plans to expand globally and roll out factory orchestration features and AI knowledge agents using proceeds from its Series A. The company has raised $38.4m in total capital to date and is led by CEO Rae Jeong and CTO Kelvin Chan.

Led · Series D · May 2026

Cagent Vascular develops endovascular devices that combine serration remodeling therapy (SRT) with intravascular lithotripsy (IVL) to treat calcified peripheral and coronary arterial disease. Its Serranator portfolio has been used in over 40,000 procedures and is sold across most major U.S. markets and in select international markets. The company recently reported first human-use cases of its Serranator SONIC IVL System within the REMODEL I prospective, multicenter study. Cagent plans to advance the technology through a global REMODEL II pivotal trial and to commercialize the SONIC IVL System in peripheral arteries while developing a coronary artery platform. The company is headquartered in Wayne, Pa.

Participated · Series B · Apr 2026

Nervonik is developing a next-generation peripheral nerve stimulation platform that combines electrical stimulation with advanced sensing to enable more precise, personalized neuromodulation therapies. Its implantable leads have demonstrated the ability to record evoked compound action potentials (ECAPs) and other physiological biomarkers. The company is advancing clinical programs and preparing for commercialization of its PNS system. Recent financing will fund further development of its proprietary sensing capabilities and support commercialization activities. Nervonik is headquartered in Los Angeles, California.

Participated · Equity · Apr 2026

Route 92 Medical develops neurovascular intervention technologies for acute ischemic stroke, notably the HiPoint Reperfusion System and its Monopoint approach to improve endovascular thrombectomy efficiency. The company completed the 250-patient SUMMIT MAX randomized trial, reporting strong safety and a high first pass effect rate. After submitting those results, the HiPoint Reperfusion System received FDA clearance in May 2025 for neurothrombectomy procedures. Route 92 has reported rapid growth in product adoption and an expanding commercial organization. With $50 million in new growth financing, the company intends to accelerate global commercial expansion, build clinical evidence for broader adoption, and continue investing in product innovation. Investors cited robust manufacturing capacity and a well-differentiated product portfolio as reasons for supporting the company’s next phase of growth.

Led · Series B · Feb 2026

Founded in 2019, Slang AI has built a custom-trained, agentic voice platform that handles inbound guest calls, books reservations, routes high-value requests and recognizes returning guests, allowing hospitality staff to focus on in-person service. The system operates 24/7 and integrates with tools such as OpenTable, SevenRooms, Tripleseat and Yelp. Slang AI claims a dataset of 25 million calls from 10 million unique guests across more than 2,000 restaurant locations, enabling 95%+ guest satisfaction, a 2× lift in phone reservations and up to 20× ROI for operators. The company has raised $68 million in funding to date and reports a sustainable competitive advantage through its proprietary data moat. Future product plans include deeper AI capabilities, multi-modal experiences, personalized recommendations, post-visit follow-ups and expanded analytics for operators. The new capital will also support scaling of engineering, product and go-to-market teams as demand surges.